Brigatinib pharmacokinetics in patients with chronic hepatic impairment
Tóm tắt
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK-positive non-small cell lung cancer. This open-label, parallel-group study investigated the effect of chronic hepatic impairment on the pharmacokinetics (PK) of brigatinib to inform dosing recommendations for these patients. Participants with hepatic impairment classified according to Child-Pugh categories of mild (A), moderate (B), or severe (C) and matched-healthy participants with normal hepatic function received a single oral dose of 90-mg brigatinib. Plasma samples were collected for the determination of brigatinib plasma protein binding and estimation of plasma PK parameters. Twenty-seven participants were enrolled (Child-Pugh A–C, n = 6 each; matched-healthy participants, n = 9). The mean fraction of free plasma brigatinib was comparable for the Child-Pugh A (11.1%), Child-Pugh B (10.8%), and healthy participant groups (8.5%); free brigatinib was higher in the Child-Pugh C group (23.1%). There were no clinically meaningful effects of mild or moderate hepatic impairment on unbound systemic exposures (area under the plasma concentration-time curve [AUC]) of brigatinib (geometric least-squares mean ratios [90% CI] of 89.32% [69.79%–114.31%] and 99.55% [77.78%–127.41%], respectively). In the severe hepatic impairment group, brigatinib unbound AUC was approximately 37% higher (geometric least-squares mean ratio [90% CI] of 137.41% [107.37%–175.86%]) compared with healthy participants with normal hepatic function. Brigatinib was well tolerated in healthy participants and in participants with hepatic impairment. No dose adjustment is required for patients with mild or moderate hepatic impairment. The brigatinib dose should be reduced by approximately 40% for patients with severe hepatic impairment.
Tài liệu tham khảo
Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT (2013) ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 19(15):4273–4281. https://doi.org/10.1158/1078-0432.Ccr-13-0318
Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115(8):1723–1733. https://doi.org/10.1002/cncr.24181
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Janne PA (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14(13):4275–4283. https://doi.org/10.1158/1078-0432.Ccr-08-0168
Gettinger SN, Huber RM, Kim D, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, Hochmair MJ, Kim S, Ahn M, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR (2022) Long-term efficacy and safety of brigatinib in crizotinib-refractory ALK+ non–small cell lung cancer: final results of the phase 1/2 and randomized phase 2 (ALTA) trials. JTO Clin Res Rep 3:100385. https://doi.org/10.1016/j.jtocrr.2022.100385
Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Holmskov Hansen K, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodriguez L, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR (2017) Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 35(22):2490–2498
Camidge DR, Kim HR, Ahn M-J, Yang JCH, Han J-Y, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim D-W, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S (2021) Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J Thorac Oncol 16(12):2091–2108. https://doi.org/10.1016/j.jtho.2021.07.035
Gupta N, Wang X, Offman E, Rich B, Kerstein D, Hanley M, Diderichsen PM, Zhang P, Venkatakrishnan K (2020) Brigatinib dose rationale in anaplastic lymphoma kinase-positive non-small cell lung cancer: exposure-response analyses of pivotal ALTA study. CPT Pharmacometrics Syst Pharmacol 9(12):718–730. https://doi.org/10.1002/psp4.12569
Gupta N, Reckamp KL, Camidge DR, Kleijn HJ, Ouerdani A, Bellanti F, Maringwa J, Hanley MJ, Wang S, Zhang P, Venkatakrishnan K (2022) Population pharmacokinetic and exposure-response analyses from ALTA-1L: model-based analyses supporting the brigatinib dose in ALK-positive NSCLC. Clin Transl Sci 15(5):1143–1154. https://doi.org/10.1111/cts.13231
Ng TL, Narasimhan N, Gupta N, Venkatakrishnan K, Kerstein D, Camidge DR (2020) Early-onset pulmonary events associated with brigatinib use in advanced NSCLC. J Thorac Oncol 15(7):1190–1199. https://doi.org/10.1016/j.jtho.2020.02.011
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR (2016) Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 17(12):1683–1696. https://doi.org/10.1016/S1470-2045(16)30392-8
Hirota T, Muraki S, Ieiri I (2019) Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Clin Pharmacokinet 58(4):403–420. https://doi.org/10.1007/s40262-018-0689-7
Tugnait M, Gupta N, Hanley MJ, Venkatakrishnan K, Sonnichsen D, Kerstein D, Dorer DJ, Narasimhan N (2019) The effect of a high-fat meal on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev 8(6):734–741. https://doi.org/10.1002/cpdd.641
Alunbrig [package insert] (2022) Takeda Pharmaceuticals America, Inc., Lexington, MA
Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K, Narasimhan N (2020) Effects of strong CYP2C8 or CYP3A inhibition and CYP3A induction on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev 9(2):214–223. https://doi.org/10.1002/cpdd.723
Gupta N, Wang X, Offman E, Prohn M, Narasimhan N, Kerstein D, Hanley MJ, Venkatakrishnan K (2021) Population pharmacokinetics of brigatinib in healthy volunteers and patients with cancer. Clin Pharmacokinet 60(2):235–247. https://doi.org/10.1007/s40262-020-00929-4
US Food and Drug Administration (2003) Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. US Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing-and
Gupta N, Hanley MJ, Kerstein D, Tugnait M, Narasimhan N, Marbury TC, Venkatakrishnan K (2021) Effect of severe renal impairment on the pharmacokinetics of brigatinib. Invest New Drugs 39:1306–1314. https://doi.org/10.1007/s10637-021-01095-5
Morcos PN, Cleary Y, Sturm-Pellanda C, Guerini E, Abt M, Donzelli M, Vazvaei F, Balas B, Parrott N, Yu L (2018) Effect of hepatic impairment on the pharmacokinetics of alectinib. J Clin Pharmacol 58(12):1618–1628. https://doi.org/10.1002/jcph.1286
Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64(12):1147–1161. https://doi.org/10.1007/s00228-008-0553-z
Yang LQ, Li SJ, Cao YF, Man XB, Yu WF, Wang HY, Wu MC (2003) Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol 9(2):359–363. https://doi.org/10.3748/wjg.v9.i2.359
Rodighiero V (1999) Effects of liver disease on pharmacokinetics. An update. Clin Pharmacokinet 37(5):399–431. https://doi.org/10.2165/00003088-199937050-00004
El-Khoueiry AB, Sarantopoulos J, O’Bryant CL, Ciombor KK, Xu H, O’Gorman M, Chakrabarti J, Usari T, El-Rayes BF (2018) Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol 81(4):659–670. https://doi.org/10.1007/s00280-018-3517-8
Xalkori [package insert] (2019) Pfizer Inc., New York, NY
Alecensa [package insert] (2021) Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
Zhao D, Chen J, Long X, Wang J (2021) Dose adjustment for tyrosine kinase inhibitors in non–small cell lung cancer patients with hepatic or renal function impairment (review). Oncol Rep 45(2):413–426. https://doi.org/10.3892/or.2020.7870
Zykadia [package insert] (2021) Novartis Pharmaceuticals Corporation, East Hanover, NJ
Lorbrena [package insert] (2021) Pfizer, Inc, New York, NY